Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.
Código da empresaINDV
Nome da EmpresaIndivior PLC
Data de listagemDec 24, 2014
CEOMr. Joseph J. (Joe) Ciaffoni
Número de funcionários1030
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 24
Endereço234 Bath Road
CidadeSLOUGH
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited Kingdom
Código postalSL1 4EE
Telefone448043791090
Sitehttps://www.indivior.com/en
Código da empresaINDV
Data de listagemDec 24, 2014
CEOMr. Joseph J. (Joe) Ciaffoni
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados